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Abstract: In this study, the influence of the presence of excipients in sample preparation and 20 
clean-up steps required prior to drug analysis in milk-based media which simulate the in vivo 21 
properties of the fed state stomach was investigated. 15 excipients, normally present in solid 22 
dosage forms of five APIs tested (atenolol, paracetamol, furosemide, nifedipine and 23 
propafenone hydrochloride) were mixed (one at a time) with the active pharmaceutical 24 
ingredient of interest either via vortexing, co-grinding or shaking of the physical mixture and 25 
dissolved in Fed State Simulated Gastric Fluid (FeSSGF).  The objective of the study was the 26 
assessment of the extraction efficiency of three protein precipitation protocols (using MeOH, 27 
ΑCN and 10% w/v TCA), typically used in drug analysis, in milk-based biorelevant media in 28 
the presence of the excipients. The mixing technique, fat content of the medium and excipient 29 
and solvent effects were investigated. The efficiency of three different protein precipitation 30 
reagents in drug extraction when dissolved as API:excipient mixtures in the fed-state medium 31 
was compared against the equivalent drug amount recovered in the absence of the excipient in 32 
FeSSGF. Most excipients had a significant negative effect (p < 0.05) on drug recovery in the 33 
milk-based medium as indicated by the multiple linear regression (MLR) analysis performed. 34 
For magnesium stearate and HPMC, the % recovery values were the lowest in four out of the 35 
five drugs studied, with a range of 10-100% depending on the API, mixing technique and 36 
protein precipitation protocol selected. The negative excipient-dependent effect was more 37 
profound in nifedipine and propafenone hydrochloride, the most lipophilic compounds of the 38 
study. Acetonitrile was the most effective extraction reagent for most drugs in the presence of 39 
excipients, followed by methanol and 10% w/v trichloroacetic acid. Data analysis also revealed 40 
a dependence of the extraction method efficiency on the medium lipid content. Application of 41 
the above extraction protocols in commercially available formulations highlighted the need for 42 
assessment of the effect of excipients in extraction efficiency, before transferring the method 43 
directly to dissolution studies of formulations in milk-based fed gastric media. In conclusion, 44 
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the presence of excipients and the selection of protein precipitation protocol are parameters 45 
which can affect significantly the efficiency of protein precipitation when FeSSGF is used as 46 
dissolution medium and need to be taken into consideration when developing a quantitative 47 
method based on the above sample clean-up technique. 48 
 49 
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1. Introduction 61 
Poor drug solubility has always been one of the biggest challenges the pharmaceutical 62 
industry has had to overcome. Approximately 40% of marketed drugs are classified as poorly 63 
soluble, while 90% of the drugs entering the screening process during drug development have 64 
poor solubility according to the Biopharmaceutics Classification System (BCS) [1]. Therefore, 65 
different formulation strategies were employed in order to improve the solubility and 66 
dissolution characteristics of the active pharmaceutical ingredients (APIs) and also act as 67 
carriers of the active substances, contributing, among others, to the formulations’ stability, 68 
appearance, biopharmaceutical profile, manufacturability and patient acceptability [2-4]. 69 
A second challenge concerns the development of media used for drug in vitro 70 
dissolution testing. Dissolution tests, as dictated by the United States Pharmacopoeia (USP) 71 
[5], cannot always provide information on the behaviour of the drugs in vivo, and therefore the 72 
need for multi-phase dissolution media able to simulate the gastrointestinal environment arose. 73 
The employment of media more “biorelevant”, targets to simulate the passage of the 74 
formulation through the different compartments of the gastrointestinal tract both in the fasted 75 
and fed states. The use of such media can contribute towards the correlation of the results of 76 
the drug in vitro release with its in vivo pharmacokinetic performance (IVIVC), with an aim to 77 
decrease the number of in vivo studies conducted pre- and post-approval [6]. As far as gastric 78 
fed environment is concerned, the media developed could be classified in two categories: i. 79 
milk-based media, such as full-fat milk, digested milk and Fed State Simulated Gastric Fluid 80 
(FeSSGF) and ii. Lipid emulsions, such as Ensure, Ensure Plus and Intralipid [7]. The 81 
media of the above two categories were developed as an attempt to simulate the gastric 82 
environment after the administration of a high or low fat standard breakfast respectively [8]. 83 
The composition of such media is constantly updated [9] and takes into consideration the 84 
protein/carbohydrate/lipid ratio and content as well as the fed gastric physicochemical 85 
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properties measured in vivo [8, 10], making reasonable compromises. A disadvantage in the 86 
use of such media concerns their treatment prior to the sample analysis, which usually requires 87 
laborious steps for the extraction of drug before its quantification. Steps which may include the 88 
precipitation of the medium’s proteins, extraction through drug partition between a mobile 89 
liquid phase and a non-miscible liquid solvent or a solid stationary phase, centrifugation and 90 
filtration are typically required prior to drug analysis. 91 
When a formulation is dissolved in such media, interactions may be formed between 92 
the excipients (excipient-excipient interactions) and also between the excipient and the active 93 
ingredient (excipient-drug interactions) or the dissolution medium (excipient-medium 94 
interactions). Not only can such interactions affect the solubility and dissolution rate of the 95 
drug in biorelevant media, but they can also play a role in the design of sample clean-up 96 
techniques, the effectiveness of which may be compromised if only designed based on the 97 
physicochemical properties of the APIs. Therefore, an appropriate design would elucidate the 98 
role of excipients in the analysis in heterogeneous biorelevant media, such as the milk-based 99 
media used for the simulation of the gastric fed state in dissolution studies, with the current 100 
study focusing on the last two types of interactions. The type of interactions between drugs and 101 
excipients are described as physical or chemical [11], depending on their ability to induce 102 
chemical changes in the drug or excipient. Binding of drugs which have primary amine 103 
functional groups in the molecule to microcrystalline cellulose is a typical example of a 104 
physical interaction, leading to drug entrapment in the cellulose [12]. Primary amines can also 105 
interact with double bonds of certain excipients, like sorbitan monooleate via a reaction 106 
analogous to Michael addition, which is considered a chemical interaction. Changes in the 107 
excipient behavior, as a result of their interaction with the heterogeneous gastric environment, 108 
have been characterised a challenge which needs to be addressed in drug dissolution and 109 
analysis [13]. A known example of interactions between excipient and medium involves 110 
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polyvinylpyrrolidone, which can form hydrogen bonds with water molecules through its 111 
carbonyl group [14], and undergo phase separation in aqueous 1.5 M potassium fluoride 112 
solutions. In cases where the milk-based or lipid emulsion-gastric biorelevant media of interest 113 
are used in drug dissolution studies, such medium-excipient interactions may be even more 114 
complicated. The formation of protein and fat gel layers around hydroxypropyl methylcellulose 115 
(HPMC) matrices, which could potentially affect drug extraction when nutrient drinks or milk 116 
are used as dissolution media, is a typical example of medium-excipient interaction [15, 16].  117 
In the present study, we investigated the impact of the presence of excipients in drug 118 
extraction when dissolved in the milk-based gastric fed state biorelevant media. Three 119 
hydrophilic (paracetamol, atenolol, furosemide; log P < 2) and two moderately lipophilic 120 
(propafenone hydrochloride and nifedipine; log P 2-4) drugs were selected as model 121 
compounds. The excipients selected for the study consist of binders, lubricants, extended 122 
release matrix agents, emulsifiers, wetting agents and disintegrants. HPMC is the most 123 
common cellulose used in hydrophilic matrices. It is used as a binder and also provides 124 
extended release characteristics to oral dosage forms [17, 18]. Magnesium stearate and stearic 125 
acid are used as tablet and capsule lubricants, avicel (microcrystalline cellulose) as binder and 126 
lubricant and povidone as binder, diluent and coating agents [18]. Tween 80 and sodium 127 
dodecyl sulfate (SLS) are employed as emulsifying, solubilizing and wetting agents [18]. 128 
Polyethylene glycols have various uses, such as suspending agents, co-solvents, binders, 129 
plasticizers or lubricants, depending on their solid state and molecular weight [18]. 130 
Croscarmellose sodium is used as disintegrant in tablets and capsules and Eudragit L100 and 131 
Eudragit E are brand names for polymethacrylate copolymers used as drug coatings for enteric 132 
drug delivery and taste masking respectively [19]. Finally carbomer 974P is used as a binder 133 
and also as suspending, gelling and emulsifying agent [18]. Drug recovery in commercially 134 
available formulations was also assessed. The impact of excipients in drug analysis in a fed 135 
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gastric medium was analysed using a regression analysis method [multiple linear regression 136 
(MLR)]. The study is a follow up of a previous study [20], where the impact of the active 137 
ingredients’ physicochemical properties (log P, ionisation, aqueous solubility and protein 138 
binding) on the extraction protocol from FeSSGF media (protein precipitation and solid phase 139 
extraction) was assessed. Twenty active substances, including the five drugs of the current 140 
study, were used as model drugs in order to assess the effect of the above physicochemical 141 
properties on the applicability of a number of extraction protocols from drugs dissolved in the 142 
middle FeSSGF version in the absence of excipients. Extractions with a variety of organic and 143 
aqueous reagents of different volumes, different SPE cartridges and elution solvents were 144 
performed. The optimum protocols, as determined in the presence of active substance only, are 145 
employed in this piece of work and their transferability in API:excipient mixtures is assessed. 146 
The objective of this work is the investigation of the impact of excipients in the efficiency 147 
(expressed as percentage of drug recovered) of the protein precipitation protocols, developed 148 
and optimized for the analysis of the APIs. Except for the drugs’ physicochemical properties, 149 
the current work aims to assess the dependence of drug-excipient mixing technique, protein 150 
precipitation extraction method, and dissolution medium’s lipid content in an attempt to 151 
provide further insight towards the optimization of drug analysis in fed state media, and the 152 
analytical methods’ application in formulations.  153 
2. Materials and methods 154 
2.1. Materials 155 
APIs: Furosemide (≥ 98% (HPLC)) and propafenone HCl (≥ 98% (HPLC)), were 156 
purchased from Sigma- Aldrich, UK. Nifedipine (98.0-102.0% (on dried substance)), 157 
paracetamol (97.5% min. (HPLC)) and atenolol (≥ 98% (TLC)) were purchased from Fisher 158 
Scientific, UK. Excipients: SLS (≥ 99.0%) (GC)), povidone K30 (meets USP testing 159 
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specifications), PEG 400 (202398), HPMC (H7509), were purchased from Sigma- Aldrich, 160 
UK. PEG 300 (Eur Pharm), stearic acid ((≥ 99.0%) (GC)) and PEG 6000 were purchased from 161 
Merck Millipore, UK. Microcrystalline cellulose (Ph-302) and croscarmellose sodium, (NF, 162 
Ph. Eur., JP) were purchased from FMC Biopolymers, UK. Carbomer 974P (Carbopol), PEG 163 
4000 and magnesium stearate (Ph.Eur., BP, USP) were purchased from Fischer Scientific, UK. 164 
Tween 80 was purchased from VWR. Eudragit E (powder) and Eudragit L100 were purchased 165 
from Evonik Industries, UK. Formulations: Adalat® LA 30 mg tb (Bayer, UK), Arythmol® 166 
300 mg tb (Abbot Healthcare, UK) Filters: Cronus 13 mm regenerated cellulose (RC) syringe 167 
filters 0.45 µm were purchased from LabHut Ltd, UK. Whatman 13 mm glass microfiber 168 
syringe filters 2.7 μm (GF/D) were purchased from Fisher Scientific, UK. 169 
Sodium acetate trihydrate, hydrochloric acid (36.5-38%), glacial acetic acid (≥ 99%), 170 
trichloroacetic acid 10% w/v and all phosphate salts were purchased from Fisher Scientific, 171 
UK. HPLC grade methanol, acetonitrile, trifluoroacetic acid (≥ 99.0%) and formic acid were 172 
all purchased from Sigma- Aldrich, UK.  173 
0, 3.6 and 5% fat UHT milk was commercially purchased (Sainsbury’s, UK). 174 
2.2. Instrumentation  175 
All samples were analysed in an HPLC system consisting of an Agilent 1200 series 176 
binary pump (G1312A), an Agilent 1200 series DAD detector (G1315D), an Agilent 1200 177 
series autosampler (G1329A), an Agilent 1200 series controller (G1316A) with a Chemstation 178 
software (Agilent Technologies, Santa Clara, United States).  179 
A pH meter Mettler-Toledo AG (model SevenCompact pH/Ion S220, Schwerzenbach, 180 
Switzerland), a centrifuge Hereus Biofuge Primo R (Thermo Scientific, Hanau, Germany) and 181 
a vortex mixer Rotamixer (HTZ, Cheshire, UK) were used.  182 
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2.3. Medium selection and preparation  183 
Fed State Simulated Gastric fluid (FeSSGF) was selected as the working fed state 184 
medium due to its simplicity in its preparation. Its buffer capacity, osmolality and surface 185 
tension values are overall closer to the values measured in vivo after the administration of a 186 
standard meal than the equivalent properties of milk, which has been extensively used as a 187 
gastric fed state medium in dissolution studies [21]. FeSSGF was prepared according to 188 
Jantratid et al [9] by mixing 3.6% fat milk and acetate buffer pH = 5 at a 1:1 volume ratio. pH 189 
was adjusted to 5 with 1 N HCl. Apart from the standard version, two other different versions 190 
of FeSSGF were prepared, using 0% w/v (FeSSGFsk) and 5% w/v (FeSSGFhf) fat milk.  191 
2.4. Selection of drug-excipient combinations  192 
 Assessment of the impact of excipients on % recovery in FeSSGF was conducted for 193 
five drugs (atenolol, paracetamol, furosemide, nifedipine, propafenone hydrochloride) selected 194 
from the study which involved the optimisation of extraction protocols for APIs of a wide range 195 
of lipophilicity, ionisation and aqueous solubility [20]. Drug working concentration was 196 
defined as the usual recommended administered single drug dose dissolved in 500 mL of 197 
medium, unless limited by the solubility of drug in FeSSGF (Table 1). In the cases where drug 198 
solubility in FeSSGF was the limiting factor, the concentrations obtained from drug solubility 199 
studies (24 h) conducted in FeSSGF [20] were used.  The current study assessed the effect of 200 
15 excipients commonly used in commercial formulations of the above drugs (Table 2), using 201 
the optimised protein precipitation protocols for the quantification of active pharmaceutical 202 
ingredients developed in the previous study [20]. In summary, the extraction protocol involves 203 
addition of 2 parts of either MeOH, or ΑCN or 10% w/v TCA in 1 part of medium, brief 204 
vortexing (30 sec), centrifugation [(8000 rpm (11400 g), 15 min, 4 °C)] and filtration through 205 
a regenerated cellulose 0.45 μm filter. The sample was diluted with “blank” acetate buffer pH 206 
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5 or MeOH:acetate buffer 1:1 pH 5, according to the drug solubility, where peak shape needed 207 
to be improved. The excipients used were selected based on the ones present in their 208 
commercial formulations as given in the Electronic Medicines Compendium (eMC) [22]. The 209 
percentage of the drug in the mixture was arbitrarily set as 30% w/w of the formulation. 210 
Extraction efficiency was given by drug (theoretical) absolute % recovery, expressed 211 
as:  212 
% absolute recovery=
amount of drug in drug−excipient mixture FeSSGF solution
amount of drug in FeSSGF drug solution
 213 
where the amount of drug in the presence of excipient was quantified against calibration 214 
standards of the drug in FeSSGF. The amount of drug in the absence of excipient was treated 215 
and analysed using the same methodology as the respective drug-excipient mixture (treated 216 
with the same protein precipitation reagent).  217 
2.5. Assessment of drug-excipient mixing process, type of medium and formulation 218 
analysis 219 
 220 
The effect of the drug mixing process was assessed in a pilot study using three (atenolol, 221 
paracetamol and propafenone) of the five drugs. The mixing method of choice was selected on 222 
the basis of method robustness and lower data variability. An appropriate quantity of drug 223 
powder (40 mg atenolol, 40 mg paracetamol, 16 mg furosemide, 12 mg nifedipine, 120 mg 224 
propafenone hydrochloride), equivalent each working concentration, was mixed for 3 minutes 225 
with one related excipient at a time by either i. Using mortar and pestle, ii. Manual shaking in 226 
an Eppendorf tube or iii. Vortexing in an Eppendorf tube. API:excipient ratios were selected 227 
based on the percentage of each excipient in commercial formulations (Table 2), within the 228 
range dictated in the “Handbook of Pharmaceutical Excipients” [18]. PEG 300 and PEG 400, 229 
which are liquid, were mixed with the drug by manual shaking in a volumetric flask for 3 min 230 
before the addition of FeSSGF. A quantity of drug-excipient mixture, containing an amount of 231 
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drug equivalent to the working drug concentration (Table 1) was transferred in a 200 mL 232 
volumetric flask and filled with FeSSGF. The flasks were incubated at 37 °C in a shaking water 233 
bath (200 shakes per min) for 90 min. Three 1 mL samples were taken from the top of each 234 
volumetric flask, filtered through GF/D filter, and each was treated with a different protein 235 
precipitation reagent (methanol, acetonitrile, 10% w/v TCA) as explained in the study for the 236 
extraction of the active pharmaceutical ingredients previously conducted [20]. The samples 237 
were filtered through 0.45 μm filters and were analysed using HPLC. Amber flasks were used 238 
for nifedipine mixtures with all experiments conducted in a light-protected environment. The 239 
autosampler, centrifuge tubes and water bath were covered in foil and amber vials were used 240 
for the HPLC analysis of nifedipine. 241 
The same process was performed in the high fat (FeSSGFhf) and no fat (FeSSGFsk) 242 
versions of FeSSGF, for the drug-excipient mixtures so as to assess the effect of the medium 243 
lipid content in drug recovery. Extractions in the above media were conducted in the mixtures 244 
initially exhibiting drug recovery < 50% in FeSSGF (MeOH used as extraction solvent). 245 
Commercial nifedipine and propefenone hydrochloride formulations (Adalat® LA tb 30 246 
mg and Arythmol® tb 300 mg) were each placed in glass bottles filled with 500 mL of FeSSGF 247 
and were incubated at 37 °C under strong agitation (200 rpm) for 48 h so as to achieve 248 
maximum drug release. A sample was taken from each flask, filtered through a GF/D syringe 249 
filter and drug was extracted with the same precipitation reagent used for the physical mixtures 250 
and analysed as explained above. All experiments were performed in triplicate and % recovery 251 
was expressed as mean ± standard deviation.  252 
Adsorption studies were performed in triplicate for each model drug for all types of 253 
filters used for each drug-solvent combination. A standard solution prepared in extraction 254 
solvent (MeOH, ΑCN, 10% w/v TCA): acetate buffer pH 5, 2:1 was filtered through the RC 255 
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and GF/D filters. The first ten drops of the filtrate were discarded and the concentration of the 256 
aliquot of the remaining filtrate was measured using HPLC. Two consecutive filtrations were 257 
performed. No adsorption issues were observed for the drugs studied (adsorption < 5%) [23] 258 
2.6. HPLC analysis 259 
Stock solutions of propafenone hydrochloride, nifedipine, atenolol, furosemide and 260 
paracetamol were prepared in MeOH. Calibration standard solutions were prepared in FeSSGF, 261 
FeSSGFhf and FeSSGFsk. The drugs were analysed in HPLC with the analytical methods 262 
(modification of published methods) used specified in the table below (Table 3). 263 
Adsorption studies were performed in triplicate for each model drug for all types of 264 
filters used. No adsorption issues were observed for the drugs studied. 265 
2.7. Statistical Analysis 266 
% absolute recovery and correlation with excipient type, mixing method and protein 267 
precipitation reagent used in drug analysis were evaluated in the context of a multi-way 268 
Analysis of Variance (ANOVA) with a post-hoc Bonferroni test (Statgraphics® v. XVI, 269 
StatPoint Technologies Inc, US). Comparisons where p < 0.05 suggested a statistically 270 
significant difference.  271 
The % recovery data was analysed via multiple linear regression (MLR) so as to 272 
investigate the impact of the selected excipient using SPSS v.22.0 (SPSS®, Chicago, IL, USA). 273 
Interactions of selected excipients with drug lipophilicity (log P) were included in the model 274 
on the basis of the lowest % recovery observed for the specific excipients (HPMC and 275 
magnesium stearate) in the pilot study. The generated MLR models were evaluated in terms of 276 
their regression coefficient (R2) and variance inflation factor (VIF) with high R2 values 277 
referring to a good fit to the model and VIF values < 3 indicating absence of multicollinearity 278 
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among the independent variables [24]. The standardized coefficients of the factors plotted 279 
indicate the relative positive/negative effect on their corresponding values. The importance of 280 
each factor was evaluated by its p value. Statistical significance was set at p < 0.05. 281 
3. Results and Discussion 282 
3.1. Effect of drug-excipient mixing technique on % drug recovery in milk-based media 283 
(pilot study) 284 
The contour graphs for the three model drugs of the pilot study express the % drug 285 
recovered as a function of type of excipient and mixing process (Fig. 1a-c) for every protein 286 
precipitation reagent (MeOH, ΑCN, 10% w/v TCA) used for their extraction. It can be 287 
observed that % recovery was affected in all three drugs; an effect denoted by the colour change 288 
across the mixing process axis (y axis). For the three compounds selected, the mixing process 289 
and the physicochemical properties of the drug substance had a significant effect on their % 290 
recovery after the medium’s protein precipitation (Fig. 2).  291 
Effect of mixing technique 292 
Vortexing and grinding gave significantly different % recovery values (p < 0.05) in all 293 
three drugs (Fig. 2), which implied that the powders’ handling may affect their homogenous 294 
mixing. In both hydrophilic drugs (paracetamol and furosemide), grinding process led to lower 295 
recovery values than in the other two mixing processes (Fig. 2). 296 
Grinding is a common strategy used to reduce drug particle size, often applied to drugs 297 
of poor solubility with an aim to increase their bioavailability in vivo [25]. Micronisation via 298 
grinding increases the drug’s specific area, leading to enhanced dissolution [26] according to 299 
the Noyes-Whitney equation. Improved dissolution is attributed to reduced particle size and 300 
consequently higher surface area and better contact of the micronised drug with the dissolution 301 
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medium [27]. Although co-grinding of drugs with several excipients, such as lactose 302 
monohydrate [28] and avicel [29] accelerated their dissolution profile, there are cases when co-303 
grinding may be used to prolong dissolution and lead to a sustained release profile [30]. A 304 
study with theophylline, a hydrophilic compound with log P value similar (log P = -0.02 [31]) 305 
to the above drugs, demonstrated that co-grinding with magnesium stearate decreased the 306 
dissolution efficiency and mean dissolution rate of the formulation [32] in comparison to a 307 
physical mixture of the same powder quantities. Therefore, a reason for the decreased drug % 308 
recovery when an excipient more hydrophobic than the active ingredient and the drug are co-309 
ground could possibly be the concentration of hydrophobic particles of decreased particle size 310 
around the API, leading to delayed drug dissolution in the fed state medium. Moreover, 311 
micronized substances can lead to higher particle agglomeration due to higher cohesion and 312 
consequently development of electrostatic charging and poor flowability properties which can 313 
affect drug handling [27]. 314 
The differences in % recovery observed between manual shaking and vortexing in the 315 
two most hydrophilic drugs can possibly be attributed to the formation of mixtures of different 316 
homogeneity; manual shaking is possibly unable to provide the mixing force required, leading 317 
to the formation of areas with increased or decreased drug concentration in the mixture, while 318 
vortexing could potentially lead to the entrapment of particles of lower density on the walls of 319 
the centrifuge tube creating similar homogeneity issues.  320 
Effect of the active substance’s properties 321 
As observed in Fig. 1a, the % recovery of paracetamol was close to 100% in the vast 322 
majority of cases with all reagents, excipients and mixing methods (mean paracetamol recovery 323 
= 100.9 ± 9.6%), a fact possibly attributed to paracetamol’s increased wettability. Contact angle 324 
measurement is a method of determination of the wettability of a compound, with angles > 90° 325 
being indicative of poor compound wettability with the dissolution medium [33]. The measured 326 
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contact angles of paracetamol’s polymorph commercially used, monoclinic form one [34], 327 
against water ranged from 15.9° (± 3.1°) to 67.7° (± 2.5°) depending on the crystal facet [35], 328 
which is indicative of increased wettability with the aqueous part of the medium. Higher 329 
wettability can lead to enhanced dissolution rate in the medium and consequently higher 330 
recovery due to the increased amount of drug solubilized in the medium. Therefore, despite 331 
paracetamol’s high polarity and lower ability to associate with fats in the medium, recovery 332 
close to 100% was obtained by using all three mixing techniques.  Recovery values > 100% 333 
can be attributed to the mixing limitations of the techniques selected and also to the inherent 334 
variability of the sample preparation due to the extraction, centrifugation and filtration steps. 335 
The % recovery values of furosemide (Fig. 1b) ranged between 40.9 and 110.2% depending on 336 
the excipient and extraction reagent used for drug recovery. Water’s contact angle against 337 
furosemide has been measured > 90° and could provide a reason for the lower recovery values 338 
compared to paracetamol [36]. The effective surface area for a specific drug substance in a 339 
solvent has been associated with the powder’s wettability, given by the contact angles in the 340 
respective solvent [37]. The wetting of a soluble agglomerate though is a multiple step process 341 
(initial wetting of the power, penetration of the liquid between different part of agglomerate, 342 
immersion into the solvent and dissolution of the particles forming the agglomerate) which 343 
cannot easily be described by a single model. It is therefore difficult to associate differences in 344 
the dissolution of the drug-excipient mixtures (and consequently differences in the amount of 345 
drug recovered) with specific effects in each of above steps caused by the drug’s or excipient’s 346 
properties [38]. The extraction values of propafenone hydrochloride, a lipophilic drug, were 347 
lower than in the two hydrophilic drugs described above (Fig. 1c, 2), and had a wider range. % 348 
recovery values were as low as 17 ± 7.9% (HPMC/shaking mixing method/drug extracted with 349 
10% w/v TCA). In this case, grinding led to significantly higher drug recovery values than in 350 
the other two mixing methods, despite the fact that some of the excipients were common in the 351 
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other drugs as well (HPMC, magnesium stearate), which suggests that the extraction efficiency 352 
in the milk-based medium depends both on the mixing process and API’s properties. 353 
The decrease in particle size and the possible alteration of the powders’ surface 354 
properties when ground with mortar and pestle were two parameters which had to be taken into 355 
consideration in assessing the effect of excipients and protein precipitation solvent. Therefore, 356 
vortexing was selected as the powder mixing method for the assessment of the above 357 
parameters in all drugs and excipients. Despite showing equally high deviation between 358 
samples with the others it was more easily controlled than manual shaking (constant stirring 359 
speed) and provided homogenous mixing with minimal changes of the powders’ surface. 360 
3.2. Effect of excipient type and extraction reagents (protein precipitation solvents) on 361 
drug % recovery in milk-based media 362 
The protein precipitation results of the full study (mixtures of the 5 drugs with the 15 363 
excipients) are presented in Fig. 3, with the drug % recovery expressed as a function of 364 
combined excipient and drug. Drugs are sorted by increasing log P values from bottom to top. 365 
Multiple linear regression analysis of the results of the full study, in combination with the 366 
multiple comparisons of the pilot study were used to evaluate the effect of the excipients and 367 
protein precipitation solvent on % drug recovery. Overall, the results of the MLR analysis of 368 
the drug-excipient mixtures for the extraction of each protein precipitation solvent showed 369 
good fits with high R2 values (0.76, 0.66 and 0.7 for the extraction with MeOH, ΑCN and 10% 370 
w/v TCA respectively) and VIF values < 3 for the independent variables of the model (Fig. 4). 371 
The analysis demonstrated statistical significance for most of the variables tested (p < 0.05).  372 
3.2.1. Excipient effect in drug recovery from milk-based media 373 
The pilot study performed with the three drugs, revealed that the % recovery is both 374 
API and excipient dependent. The multiple comparisons’ test performed with the three drugs 375 
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showed that in all cases, their mixtures with magnesium stearate and HPMC led to significantly 376 
different recoveries compared to the rest of the drug-excipient mixtures, with lower mean % 377 
recovery values (Fig. 2). When the excipient effect was evaluated for all five drugs (vortexing), 378 
decreased % recovery values were observed in more drug-excipient mixtures in addition to the 379 
two mentioned above, denoted by the blue and green zones in the contour plots of the vortexed 380 
mixtures (Fig. 3). Furthermore, most excipients showed a statistically significant negative 381 
effect on % drug recovery, as demonstrated by the results of the MLR analysis (Fig. 4), with 382 
the excipient effect discussed for each drug separately below. From the contour map of the full 383 
study (Fig. 3), it can be observed that the recovery values for the three hydrophilic drugs 384 
(atenolol, paracetamol, furosemide) were distinctively higher than in the mixtures of the 385 
lipophilic ones (nifedipine, propafenone hydrochloride).  386 
In the case of paracetamol, none of the excipients decreased % drug recovery more than 387 
15% except for HPMC, which was attributed to the drug increased wettability as reported 388 
above. When HPMC was mixed with other active ingredients as well, (atenolol, nifedipine, 389 
propafenone hydrochloride) the % recovery of the drugs ranged from approximately 80 % for 390 
paracetamol down to approximately 20% for propafenone hydrochloride, regardless of the 391 
extraction solvent of choice (Fig. 3). In the cases of HPMC and magnesium stearate for 392 
atenolol, recovery values as low as 61.3 and 56.9% were observed for the two excipients 393 
respectively. In furosemide mixtures, the drug recovery was mainly controlled by the extraction 394 
reagent, rather than the excipient. an effect discussed in the section below. One possible reason 395 
for the lower recovery in the presence of HPMC could be the formation of a barrier of fat and/or 396 
proteins formed around the powder in the milk-based medium, decreasing medium permeation 397 
[39] to the inner part of the formulation, as reported in several studies where nutrient drinks 398 
like Ensure Plus® or Nutrison® were used as fed gastric dissolution media [15] [40]. It was also 399 
demonstrated that the initial gel formation layer of HPMC matrices during dissolution 400 
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increased according to the fat percentage of the fed state medium, although the difference could 401 
be attributed to other properties of the medium, such as its viscosity [16]. Magnesium stearate 402 
acts by preventing the adhesion of the powder during tablet compression, forming a non-403 
uniform hydrophobic layer on the surface of the powder mixture [41, 42]. Therefore, the 404 
decreased % recovery values in all drugs mixed with magnesium stearate could be attributed 405 
to the slower drug dissolution in the medium, due to the excipient’s hydrophobic nature [43]. 406 
Interestingly, although most excipients demonstrated a significant negative effect on drug % 407 
recovery (green bars), and HPMC and magnesium stearate showed a negative effect in the 408 
multiple comparisons test of the pilot study, they did not have a statistically significant 409 
contribution to the MLR final model (Fig. 4). Their interactions with drug lipophilicity though 410 
demonstrated a highly significant effect, as shown by the high standardized coefficients of the 411 
respective variables (HPMC*log P, magnesium stearate*log P) (Fig. 4). In the case of 412 
propafenone, a more lipophilic drug, drug recovery in the presence of HPMC and magnesium 413 
stearate was significantly lower than in the presence of the other excipients (p < 0.05) (Fig. 2). 414 
% recovery values were the lowest in the presence of the former, and did not exceed 40% 415 
regardless of the choice of the extraction solvent. The challenging nature of the extraction of 416 
lipophilic drugs from HPMC matrixes has been reported and attributed to the high API 417 
lipophilicity and the gelation properties of the polymer [44], an effect demonstrated in the 418 
current study too, as indicated by the high negative HPMC*log P standardised coefficients in 419 
MLR analysis (Fig. 4). Therefore, the negative impact of HPMC and magnesium stearate on 420 
drug recovery is more profound in drugs of high lipophilicity (log P) and can attributed to the 421 
possible formation of layers around the drug powder either self-induced or in combination with 422 
the milk-based medium [15, 41, 42].  423 
A similar explanation could be given for the negative effect of povidone K30, a 424 
hydrophilic polymer which has been shown to increase both wettability and dissolution rate of 425 
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lovastatin, a drug of similar lipophilicity to the lipophilic drugs (nifedipine, propafenone 426 
hydrochloride) of the study [45] (log P = 4.26 [31]). 427 
As far as the effect of the excipient on the dissolution of the lipophilic drugs is 428 
concerned, the short duration of the study (90 min) seems to be the most probable reason for 429 
the log P/excipient-dependent % recovery. Most of the excipients appear to have a log P- 430 
dependent effect on the dissolution of the APIs, meaning that a time > 90 min would be required 431 
for the total amount of lipophilic drugs to be solubilized.  The combinations of nifedipine with 432 
all excipients demonstrated % recovery values < 80%. Except for the HPMC and magnesium 433 
stearate, the effect of which on drug dissolution was previously described, the lowest values 434 
reported for nifedipine were in its mixtures with Eudragit L100, Eudragit E and carbopol 974P. 435 
Eudragit L100 is insoluble below pH 6, according to the manufacturer, which could result in 436 
co-precipitation of the drug in the FeSSGF of pH= 5. According to the excipients’ product 437 
characteristics, Eudragit polymers are highly soluble in polar organic solvents and 1N HCl, 438 
which indicates that the above excipients are more likely to act as recovery enhancers rather 439 
than prohibitors.  Eudragit E is soluble at gastric fluid of pH up to 5, meaning that in the 440 
working pH, after the addition of methanol or acetonitrile, precipitation of the excipient along 441 
with the drug could take place due to the pH of the supernatant (pH of the supernatant measured 442 
> 5). The reason of the decreased drug recovery values when APIs were mixed with carbopol 443 
974P can be attributed to the same reason as HPMC and magnesium stearate; the formation of 444 
a gel layer around the particles of the active ingredient decreasing the diffusion coefficient of 445 
the drug in the medium [46]. Another possible mechanism suggesting reduced drug transport 446 
to the dissolution medium due to interaction between the drug and the polymer has also been 447 
reported in the literature [47]. Avicel’s negative effect on nifedipine recovery (< 60% with all 448 
protein precipitation reagents) (Fig. 3) could also be attributed to the entrapment of the smaller 449 
drug particles between the microcrystalline cellulose’s particles leading to slower drug wetting 450 
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and dissolution [48]. Water soluble polyethylene glycols (PEG 4000, PEG 6000) and Tween 451 
80 were normally expected not to affect % drug recovery negatively, as they act as solubility 452 
enhancers [49] and surfactants [50], improving the solubility and dissolution characteristics of 453 
poorly soluble drugs. The effect of PEG 300 and SLS in atenolol recovery was minimal (> 454 
79.5% in all mixtures), while the % recovery in the presence of avicel, croscarmellose sodium 455 
and magnesium stearate were all approximately 60, 80 and 100% when 10% w/v TCA, MeOH 456 
and ΑCN were used for the extraction of drug from FeSSGF respectively (Fig. 3).  457 
Despite the different impact of each excipient on drug recovery, the study design did 458 
not account for the effect of absolute excipient and drug concentrations in the working 459 
solutions. Hence, the drug-excipient effect was assessed as an entity, with the drug:excipient 460 
ratio being the constant parameter in all cases. Despite the representative ratios used in the 461 
study, to the best of our knowledge, keeping a different variable constant such as the active 462 
substance or concentration could potentially lead to different conclusions. 463 
3.2.2. Protein precipitation reagent effect in drug recovery from milk-based media 464 
For the three hydrophilic drugs (atenolol, paracetamol, furosemide), recovery values > 465 
60% were observed for all three reagents (Fig. 3), with the highest recovery observed in ΑCN 466 
extraction, as the red zones of the graph (Fig. 3) indicate. In regard to the lipophilic drugs 467 
(nifedipine, propafenone hydrochloride), the amounts of drug extracted were distinctively 468 
lower for all three reagents. Particularly for 10% w/v TCA, the percentage of drug recovered 469 
in the presence of excipients was extremely low; less than 40% of the drug was recovered in 470 
15 of the total 16 nifedipine/propafenone hydrochloride and excipient mixtures (Fig. 3). At the 471 
TCA concentrations used, unfolding of the medium’s proteins is set off by negatively charged 472 
ions of the acid, which cause the disruption of the electrostatic forces maintaining the structure 473 
of its proteins. This mechanism of action can potentially expose non-polar protein surfaces and 474 
lead to coalescence of the molecules and precipitation [51]. It is possible that the presence of 475 
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excipients may inhibit the solubilisation of the drugs by the acid and facilitate its occlusion in 476 
the precipitate.  477 
The effect of the type of protein precipitation solvent was statistically significant in 478 
terms of % recovery (p < 0.05), as demonstrated by the ANOVA analysis of the pilot study 479 
(Fig. 2). The differences can be observed in the different reagent levels of the visual ANOVA 480 
representation (Fig. 2) and also in the different colour zones of the contour graphs (Fig. 3); the 481 
reddest zones observed belong to ΑCN and the bluest to 10% w/v TCA, indicating the highest 482 
and lowest recovery values respectively. The above order of extraction efficiency (ΑCN > 483 
MeOH > 10% w/v TCA) was followed in four of the five drugs regardless of excipient of 484 
mixing method, except for atenolol as observed in the contour plots (Fig. 1, 3). In the case of 485 
atenolol mixtures, which was the only drug more poorly extracted with ΑCN than with TCA, 486 
the better applicability of trichloroacetic acid cannot be directly justified by the drug’s 487 
physicochemical properties, as in the absence of excipient both ΑCN and 10% w/v TCA were 488 
able to recover approximately 100% of the drug in FeSSGF [20]. It could be suggested that 489 
drug’s comparatively higher solubility in trichloroacetic acid than in acetonitrile [52] led to 490 
faster drug solubilisation in its mixture with the excipient. The similarity in the contour patterns 491 
and the standardized coefficients of MeOH and ΑCN in Figures 3 and 4, respectively, and their 492 
dissimilarity to those of TCA, highlight the impact of solvent strength and polarity on drug 493 
recovery, which is expected and highly dependent on the compounds’ non-polar characteristics. 494 
It is worth mentioning, that the extraction efficiency (in terms of effective drug 495 
recovery) of the three reagents used in the presence of excipients, followed the same pattern as 496 
in their absence, as demonstrated in a previous study [20]. In both studies, drug lipophilicity 497 
had a negative effect on the amount of drug recovered, which may suggest that the presence of 498 
excipients may amplify the differences in drug recovery, previously correlated with the drug’s 499 
physicochemical properties. It should be clarified that the negative effect of lipophilicity is 500 
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attributed to the drug’s decreased dissolution rate in the medium, rather than the effect of the 501 
excipient in extraction efficiency. This is also supported by a previous study in drug extraction 502 
in FeSSGF [53], which did not show any statistically significant correlations between drug 503 
lipophilicity and sample treatment efficiency using MeOH or ΑCN. Studies using liquid 504 
extraction techniques as a means for sample treatment prior to analysis in milk have 505 
demonstrated the effect of solvent polarity in drug recovery [54]. and the importance of solvent 506 
miscibility with the aqueous phase and their salting-out potential [55]. 507 
Therefore, the physicochemical properties of the API need to be taken into 508 
consideration in the design of an effective sample clean-up method, both in the absence and 509 
presence of excipients.  510 
3.3. Effect of medium fat content on drug %recovery in milk-based media and assessment 511 
of drug extraction method in solid oral dosage forms  512 
Analysis in media of different fat content was performed for the two lipophilic drugs 513 
of the study, nifedipine and propafenone hydrochloride, in mixtures with excipients 514 
demonstrating the low (< 50%) drug % recovery (magnesium stearate, carbomer 974P, 515 
Eudragit L100 and HPMC).  516 
The recoveries in the high and no fat media for the excipient mixtures with nifedipine 517 
were equally low. Nifedipine recovered ranged from approximately 3 to 16% and from 4 to 518 
18% for the low and high fat medium, while the equivalent values for FeSSGF gave values 519 
from 7 to 50% for the three reagents used (Fig. 5). The reduced values in the low fat medium, 520 
compared to FeSSGF, were attributed to the lower drug solubility. Nifedipine’s solubility in 521 
FeSSGF is approximately 70 μg/mL [56]; a value approximately 7 to 10-fold higher than the 522 
drug’s aqueous solubility, with the difference possibly attributed to the solubilisation of the 523 
lipophilic drug in the lipid portion of the medium. Therefore, the absence of fat in the medium 524 
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may be the reason for the lower drug solubility and consequently lower recovery. In the high-525 
fat medium, low recovery values are possibly attributed to the decreased extraction efficiency 526 
in media of high fat content, a common issue of sample clean-up methods in milk-based media 527 
[7]. A study of HPMC-nimodipine mixtures in acetate buffer pH = 4.5 (log P = 3.41 [57], 528 
similar structure and lipophilicity to nifedipine) showed an increase in the drug solubility and 529 
dissolution efficiency by a factor of 4 compared to the drug in the absence of the excipient [58]. 530 
The above points out that low solubility and dissolution rates cannot always be attributed to 531 
the excipient but to the interactions between the mixture and the dissolution medium as well. 532 
In the case of propafenone, medium prepared with skimmed milk (FeSSGFsk) gave higher drug 533 
recovery values when ΑCN and TCA were used as protein precipitation reagents (Fig. 5), 534 
which could be  attributed to the difficulty of designing an effective extraction protocol in 535 
media of high lipid content. Propafenone, as a lipophilic compound was expected to have 536 
higher solubility in the full fat medium, due to its preferential distribution in its lipid portion. 537 
Lower recovery can possibly be attributed to the decreased extraction strength of the solvents 538 
due to the drug’s distribution to the medium’s fat. 539 
Extraction of drug of commercial formulations revealed that despite the presence of the 540 
excipients, their extraction was in no case affected to such an extent as with the simple mixing 541 
of each excipient separately. The % recovery value was in all cases between 67.2 and 99.5% 542 
(Fig. 5a, b) and its dependence on the solvent selection was evident, in the same way as with 543 
the physical mixtures of APIs and excipients. Acetonitrile was most effective, followed by 544 
methanol and 10% w/v TCA. The reagent-dependent recovery results in drug formulation 545 
indicate that suitability of the extraction method for the active ingredient does not necessarily 546 
guarantee equivalent extraction performance in formulation analysis. The reduced recovery in 547 
extraction with trichloroacetic acid may indicate entrapment or adsorption of the drug in 548 
excipients, and inability of the method to break these excipient-drug interactions. A use of such 549 
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a method without prior assessment of drug-excipient interactions could lead to erroneous 550 
results if potentially used for drug quantification in a dissolution study using milk-based media. 551 
The differences in recovery values among formulations and reagents, along with the results of 552 
the assessment of the mixing technique, confirmed that the process via which drugs and 553 
excipients are formulated has to be considered for the development and optimisation of a 554 
sample clean-up protocol. As the differences reported between drug-excipient mixtures point 555 
out, the conclusions of the current study are not directly transferable to the commercial 556 
formulations. Excipients during formulation development undergo several changes resulting 557 
from the nature of the manufacturing process. An increase in the tablet’s surface area as a result 558 
of direct compression [59] or formation of granules of different size, porosity and friability 559 
[60] may lead to different drug dissolution behavior in fed state media. However, good 560 
knowledge of the excipients effect in drug analysis could potentially be used in the optimisation 561 
of sample treatment and drug analysis in the process of formulation development when 562 
excipients are one at a time, or in formulations in which the excipients undergo minimal 563 
changes in terms of their physicochemical characteristics (e.g oral solutions). 564 
4. Conclusions 565 
The presence of excipients can have an effect on the amount of drug extracted from 566 
milk-based gastric media and should therefore be taken into consideration when developing a 567 
quantitative method for drug analysis. Using a previously developed extraction protocol [20], 568 
the effect of excipients used in commercial formulations in the recovery of drugs when 569 
dissolved in milk-based fed gastric media was investigated. The results demonstrated 570 
dependence of the type of excipient, mixing technique and protein precipitation protocol 571 
selected with the interaction between lipophilicity and certain excipients (HPMC, magnesium 572 
stearate) being highly influential in most cases, as indicated by the MLR analysis. The 573 
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differences in the impact of the same excipients in drugs of different lipophilicity highlighted 574 
the need for further investigation of excipient-drug interactions and the way both the 575 
excipients’ and APIs’ physicochemical properties can affect drug analysis in fed state gastric 576 
media. The study revealed a medium-dependent recovery in the presence of excipients, but 577 
without indications of a direct correlation between medium’s fat percentage and amount of 578 
drug recovered. Finally, it was concluded that excipient processing during drug manufacturing 579 
may affect the efficiency of the sample clean-up methods and has to be taken into consideration 580 
in drug analysis and quantification. Therefore, to accomplish the accuracy required in drug 581 
analysis in fed state milk-based media, the effect of drug properties, type of excipient, changes 582 
in medium composition and formulation manufacturing have to be individually assessed in 583 
regard of their effect on the extraction efficiency.  A more complete understanding of the effect 584 
of the above characteristics on drug recovery, further testing of a more extensive set of drugs, 585 
excipients and reagents could potentially allow the optimization of the sample treatment 586 
process in fed media using reduced screening approaches. Further studies which will assess the 587 
full applicability of the optimized extraction protocols developed for the active pharmaceutical 588 
ingredients on the different types of drug formulations are required.  589 
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List of tables 792 
Table 1 Physicochemical properties and working concentrations of model compounds. 793 
Drug 






Atenolol 0.23 9.60 200 
Paracetamol 0.46 9.50     200 
Furosemide 0.74 3.90 80 
Nifedipine 2.91 3.93 60 
Propafenone 
hydrochloride 





Table 2 Mixtures and ratios of excipients and APIs used. “” denotes the presence of each 796 







Nifedipine Atenolol Drug:excipient 
ratio in the 
mixture 
Povidone K30      10:1 
HPMC      0.6:1 
Microcrystalline 
cellulose (Avicel) 
     1.2:1 
SLS      20:1 
Carbopol 974P      6:1 
Eudragit E      3:1 
Eudragit L100      3:1 
Magnesium Stearate      10:1 
Stearic acid      10:1 
Tween 80      10:1 
PEG 300      10:1 
PEG 400      
PEG 4000      
PEG 6000      
Croscarmellose sodium      10:1 
a Drug: excipient ratio value was selected within the range of % excipient concentration as dictated in “Handbook of 798 
Pharmaceutical excipients” [18]. 799 




Table 3 HPLC methods (modification of published methods) used for the quantification of the 802 
model compounds. 803 












BDS C18, 300Å, 









BDS C18, 300Å, 
250 x 4.6 mm, 5 
μm 
MeOH:Formic 
acid 0.1% v/v 
60:40 




BDS C18, 300Å, 









BDS C18, 300Å, 






(pH = 4.5) 
20:80 





XDB C18, 120Å, 





100 pH = 2.9 
0.8  25  20  248 
 804 
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Figure captions 806 
Fig. 1. Drug-excipient gradient maps for a. paracetamol, b. furosemide and c. propafenone 807 
hydrochloride. Contour plot of % recovery values as a function of drug-excipient mixing 808 
method and excipient. “Warm” colour regions (yellow, red) indicate that amounts of drug 809 
similar to their theoretical recovery values in the absence of excipient (% recovery > 80%) 810 
were able to be extracted from the medium, whereas “cold” regions (blue, purple) are indicative 811 
of poor % drug recovery. 812 
Fig. 2. Three-way ANOVA of excipient, protein precipitation reagent and mixing method 813 
effects (from left to right) on % drug recovery for the three model drugs. Different letters denote 814 
statistically different % recovery between excipients, reagents or mixing processes (p < 0.05). 815 
Fig. 3. Drug-excipient gradient map (mixed by vortexing). Contour plot of % recovery values 816 
as a function of drug and excipient. Red x points denote the drug-excipient combinations used 817 
in the mixtures. 818 
Fig. 4. Standardised coefficients of MLR analysis after protein precipitation with a. MeOH, b. 819 
ΑCN and c. 10% w/v TCA. Green colour denotes statistical significance. 820 
Fig. 5 Nifedipine-excipient (a.) and propafenone-excipient (b.) mixtures, media and 821 
commercial formulations gradient map. Contour plot of % recovery values as a function of 822 
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